ValuEngine upgraded shares of Icon (NASDAQ:ICLR) from a hold rating to a buy rating in a report issued on Tuesday morning.
Other equities analysts have also issued research reports about the company. KeyCorp reaffirmed a buy rating and issued a $130.00 price target on shares of Icon in a research note on Thursday, January 11th. Zacks Investment Research lowered Icon from a buy rating to a hold rating in a research note on Wednesday, November 1st. Mizuho set a $109.00 price target on Icon and gave the company a hold rating in a research note on Wednesday, January 24th. BidaskClub raised Icon from a strong sell rating to a sell rating in a research note on Friday, February 9th. Finally, Barclays upped their price target on Icon from $108.00 to $120.00 and gave the company an equal weight rating in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $124.55.
Icon (NASDAQ ICLR) opened at $109.36 on Tuesday. Icon has a 12 month low of $76.46 and a 12 month high of $124.48. The company has a market capitalization of $5,910.00, a price-to-earnings ratio of 21.23, a PEG ratio of 1.51 and a beta of 0.48. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Financial Gravity Companies Inc. acquired a new position in Icon during the 4th quarter worth about $144,000. SG Americas Securities LLC acquired a new stake in Icon in the 3rd quarter valued at about $148,000. C M Bidwell & Associates Ltd. acquired a new stake in Icon in the 4th quarter valued at about $196,000. Advisor Partners LLC acquired a new stake in Icon in the 4th quarter valued at about $201,000. Finally, Dean Capital Investments Management LLC acquired a new stake in Icon in the 4th quarter valued at about $203,000. 89.66% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/14/icon-iclr-upgraded-to-buy-by-valuengine.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.